Idiopathic Pulmonary Fibrosis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Idiopathic Pulmonary Fibrosis Market is segmented by Drug Type (Nintedanib, Pirfenidone, and Other Drug Types), Mode of Action (Antifibrotic Agents, Tyrosine Kinase Inhibitors, and Other Modes of Action), End User (Hospitals and Clinics and Other End Users), and Geography.

Market Snapshot

Idiopathic Pulmonary Fibrosis Market Overview
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 9.5 %
Idiopathic Pulmonary Fibrosis Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The idiopathic pulmonary fibrosis market studied is anticipated to register a CAGR of nearly 9.5%, during the forecast period.

  • Certain factors that are driving the market growth include increasing prevalence of idiopathic pulmonary fibrosis and rising research and development activities.
  • Idiopathic pulmonary fibrosis (IPF) is a rare, but serious lung disease. This leads to a build-up of scar tissue in the lungs, which stiffens the lungs to an extent where they are unable to expand and contract.
  • According to the National Institutes of Health, about 100,000 people in the United States have IPF, and approximately 30,000 to 40,000 new cases are found each year. Across the world, the incidence of IPF is estimated to be 10.7 cases per 100,000 person-years for males and 7.4 cases per 100,000 person-years for females. The prevalence of idiopathic pulmonary fibrosis is estimated to be 20 cases per 100,000 persons for males and 13 cases per 100,000 persons for females.
  • While it is hard to pinpoint who exactly gets IPF, one recent studyTrusted Source reported that more American men are diagnosed with the disease than women. Another predictive factor is age. A large number of studies have reported that older age is a common diagnosis factor of IPF. Owing to these factors, the market is expected to grow at a steady pace over the forecast period.

Scope of the Report

IPF refers to a type of lung disease which causes scarring (fibrosis) of the lungs for an unknown reason. As time passes, this scarring gets worse and it becomes hard to take in a deep breath and the lungs cannot take in enough oxygen. IPF is a type of interstitial lung disease, mainly involving the interstitium (the tissue and space around the air sacs of the lungs), and not directly involving the airways or blood vessels.

By Drug Type
Nintedanib
Pirfenidone
Other Drug Types
By Mode of Action
Antifibrotic Agents
Tyrosine Kinase Inhibitors
Other Modes of Action
By End User
Hospitals and Clinics
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Pirfenidone Holds Significant Share in the Global Idiopathic Pulmonary Fibrosis Market

  • Pirfenidone is an antifibrotic compound approved for the treatment of IPF. Together with nintedanib, the second antifibrotic compound, pirfenidone has received the label of “conditional recommendation for IPF treatment” in the recent update of the ATS/ERS/JRS/ALAT 2015 statement.
  • Esbriet is an oral pirfenidone approved for the treatment of IPF and is available in around 40 countries worldwide. Esbriet has Orphan Drug Designation and was approved for use in Europe in 2011 in adults with mild-to-moderate IPF and in the US in people with IPF in October 2014.
  • In 2017, the US Food and Drug Administration (FDA) and the European Commission approved the Esbriet 801 mg and 267 mg tablets as new options for administering the medicine for the treatment of IPF.
Idiopathic Pulmonary Fibrosis Market Revenue Share

North America Dominates the Global Idiopathic Pulmonary Fibrosis Market

  • The United States had the most significant share of the idiopathic pulmonary fibrosis market in North America, due to the increasing incidence of the disease, along with the rising geriatric population and smoking habits.
  • As per the data published by the American IPF Foundation, the incidence of idiopathic pulmonary fibrosis (IPF) doubled over the decade. An estimated 50,000 people die from IPF in the United States each year, more deaths than from breast cancer.
  • The aforementioned statistic does not include the high percentage of people who are never diagnosed. Scientists agree that the extent of deaths is still not known or defined properly and, hence, more research is needed.
  • Recently, the CDC identified a statistically significant cluster of IPF patients diagnosed at a Virginia medical center. Overall, the rising prevalence of the disease is anticipated to drive the market growth across the region.
Idiopathic Pulmonary Fibrosis Market Growth Rate By Region

Competitive Landscape

The market is competitive and consists of a few major players. In February 2020, Roche successfully completed its purchase of Promedior Inc., along with its entire portfolio of fibrotic disease therapeutics. Companies, like Afferent Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen, Genentech USA Inc., Jubilant Cadista, Merck & Co. Inc., Prometic Life Sciences, among others, hold the substantial market share in the market.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Idiopathic Pulmonary Fibrosis

      2. 4.2.2 Rising Research and Development Activities in Fibrotic Diseases

    3. 4.3 Market Restraints

      1. 4.3.1 Unavailability of Proper Treatment and Lack of Awareness in Developing Countries

    4. 4.4 Porter's Five Force Analysiss

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Type

      1. 5.1.1 Nintedanib

      2. 5.1.2 Pirfenidone

      3. 5.1.3 Other Drug Types

    2. 5.2 By Mode of Action

      1. 5.2.1 Antifibrotic Agents

      2. 5.2.2 Tyrosine Kinase Inhibitors

      3. 5.2.3 Other Modes of Action

    3. 5.3 By End User

      1. 5.3.1 Hospitals and Clinics

      2. 5.3.2 Other End Users

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Afferent Pharmaceuticals

      2. 6.1.2 Boehringer Ingelheim

      3. 6.1.3 Bristol-Myers Squibb

      4. 6.1.4 Cipla Inc.

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 FibroGen

      7. 6.1.7 Genentech USA Inc.

      8. 6.1.8 Jubilant Cadista

      9. 6.1.9 Merck & Co. Inc.

      10. 6.1.10 Prometic Life Sciences

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Idiopathic Pulmonary Fibrosis Market market is studied from 2018 - 2026.

The Idiopathic Pulmonary Fibrosis Market is growing at a CAGR of 9.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

F. Hoffmann-La Roche Ltd , Boehringer Ingelheim , Cipla Inc. , Genentech USA, Inc. , Jubilant Cadista are the major companies operating in Idiopathic Pulmonary Fibrosis Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!